ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com



2026Äê1ÔÂ11ÈÕ£¬£¬£¬£¬£¬ÃÀ¹ú¾É½ðɽÖÞ¼ÊÂùÝ
ACCESS ASIAҩͨÑÇÖÞBDÂÛ̳¿ªÄ»ÔÚ¼´£¡
ÃÀ¸ß÷×÷ÎªÌØÑûÔÞÖú·½¼°Ñݽ²¼Î±ö£¬£¬£¬£¬£¬³ÏÑûÄúÇ×ÁÙÏÖ³¡£¬£¬£¬£¬£¬ÅäºÏ¼ÓÈëÒ»³¡È«ÇòÉúÎïÒ½Ò©Ñз¢ÕߵĶԻ°¡£¡£¡£¡£¡£

ÃÀ¸ß÷ʼÖÕÖÂÁ¦ÓÚ³ÉΪȫÇòÒ©ÎïÑз¢Õß´Ó·¢Ã÷¹âÁÙ´²µÄ×î¿É¿¿ÏàÖúͬ°é¡£¡£¡£¡£¡£´Ë´ÎÂÛ̳£¬£¬£¬£¬£¬ÃÀ¸ß÷¸ß¹ÜÍŶӽ«Éî¶È¼ÓÈ룺
Ö÷ÌâÑݽ²£º
ÃÀ¸ß÷ҩÎï·¢Ã÷¼°Ò©Ñ§Ñо¿ÊÂÒµ²¿×ܲöÎïʥ²©Ê¿½«´øÀ´Ö÷ÌâÑݽ²£º¡°How China's CRO-Driven Innovation Ecosystem Fuels Asset Incubation and Global Deal Flow¡±
Ô²×ÀÌÖÂÛ£º
ÃÀ¸ß÷ÃÀ¹ú¹«Ë¾×ܲÃÁÖÇì´Ï²©Ê¿½«Ö÷³ÖרÌâ×êÑУº¡°From Transactions to Global Stage - Strategies and Opportunities for Chinese Innovative Drug Assets¡±
ÍíÑçÖ´ǣº
ÃÀ¸ß÷Ê×´´ÈË¡¢¶Ê³¤¼æÊ×ϯִÐйٳ´º÷벩ʿ½«½ÒÏþÍíÑ翪³¡Ö´ǡ£¡£¡£¡£¡£

¡¶The Blueprint: A Portfolio of Executed Programs¡·
Õâ±¾ÃÀ¸ß÷¿Í»§µÄÀ¶Í¼»²áÈ«ÐÄËѼ¯ÁËÓÉÎÒÃÇÈ«ÇòÏàÖúͬ°éÌá½»µÄÑз¢ÏîÄ¿Óë¹ÜÏß°¸Àý¡£¡£¡£¡£¡£Ëü¼Í¼ÁËÒ»¸ö¸ö´Ó¿´·¨×ßÏòINDÒÔÖ¸üÔ¶½×¶ÎµÄÁ¢Òì¹ÊÊ£¬£¬£¬£¬£¬Êǿͻ§Öǻۡ¢ÓÂÆøÓë¿ÆÑ§¾«ÉñµÄ½á¾§¡£¡£¡£¡£¡£ÃÀ¸ß÷ºÜÐÒÔË×÷ΪÑз¢Ð§ÀÍͬ°é£¬£¬£¬£¬£¬ÔÚÕâЩÀï³Ì±®ÖÐТ˳ÁËÃÀ¸ß÷רҵʵÁ¦¡£¡£¡£¡£¡£
Õâ·ÝÀ¶Í¼£¬£¬£¬£¬£¬ÊÇÎÒÃǶÔËùÓÐÐÅÈÎÃÀ¸ß÷µÄ¿Í»§µÄÖ¾´£¬£¬£¬£¬£¬Ò²ÊǶÔδÀ´Ç±ÔÚÏàÖúͬ°éµÄÒ»·ÝÖÁÐÄÔ¼Ç롪¡ªÔÚÕâÀ£¬£¬£¬£¬ÄúÄÜ¿´µ½ÓëÎÒÃÇÙÉÐÐËùÄִܵïµÄÔ¶·½¡£¡£¡£¡£¡£
»¶ÓݰÁÙÃÀ¸ß÷½»Á÷Çø£¬£¬£¬£¬£¬·ÔÄÕâ·Ý³ÐÔØ×ÅÐÅÈÎÓëЧ¹ûµÄÖ½ÖÊ»²á£¬£¬£¬£¬£¬»òÔ¤Ô¼»ñÈ¡µç×Ó°æ±¾¡£¡£¡£¡£¡£
±¾½ìÂÛ̳½«ÓÐÊýÊ®¼Ò¿ç¹úÒ©ÆóÓëÉúÎï¿Æ¼¼¹«Ë¾¾ÙÐйÜÏß¼°ÏîĿչʾ£¬£¬£¬£¬£¬ÁýÕÖ´ÓÔçÆÚ·¢Ã÷¹âÁÙ´²¿ª·¢µÄÈ«½×¶ÎÈÈÃÅ¡£¡£¡£¡£¡£
ÃÀ¸ß÷ÍŶӽ«ÔÚÏÖ³¡ÓëÄúÅäºÏ̽ÌÖ£º
? ÖØ´ó·Ö×Ó£¨ÈçADC¡¢ºËËáÒ©¡¢PROTAC¡¢CGTµÈ£©µÄÈ«Çò¿ª·¢²ßÂÔ£»£»£»£»£»
? ÖÐÃÀË«±¨¼°¹ú¼ÊÉ걨µÄ¸ßЧ·¾¶£»£»£»£»£»
? ÔçÆÚÑз¢ÓëCMCÎÞ·ìÏνӵÄÒ»Ì廯¼Æ»®£»£»£»£»£»
? .......
·¢ËÍÓʼþÖÁmarketing@medicilon.com£¬£¬£¬£¬£¬Ô¤Ô¼ÓëÃÀ¸ß÷ÍŶÓÏÖ³¡Ì¸ÅС£¡£¡£¡£¡£
ÎÒÃǴÇÅÁº£¬£¬£¬£¬£¬ÖúÄú³É¼¨À¶Í¼¡£¡£¡£¡£¡£
2026Äê1ÔÂ11ÈÕ£¬£¬£¬£¬£¬¾É½ðɽ¼û£¡

Ïà¹ØÐÂÎÅʱ¼ä£º2020Äê03ÔÂ27ÈÕ 14:00-15:00
ËùÔÚ£ºÏßÉÏÖ±²¥
ʱ¼ä£º2018Äê10ÔÂ17-19ÈÕ
ËùÔÚ£º³É¶¼Ê××ùÍòºÀÂùÝ